Cytovale, based in San Francisco, Calif., is a medical technology company dedicated to revolutionizing diagnostics using cell mechanics and machine learning, and applying this first to sepsis, a condition whose early detection dramatically improves patient outcomes.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/30/19 | $7,400,000 | Series B Extension |
Blackhorn Ventures Breakout Ventures Western Technology Investment | undisclosed |
| 10/10/24 | $100,000,000 | Series D |
Breakout Ventures Canada Pension Plan Investment Board Global Health Investment Fund Norwest Venture Partners Sands Capital | undisclosed |
